We thank Dr. Hsu and Dr. Lai for their interest in our work on COVID-19 and Long-COVID.
We fully agree with them on the fact that several factors need to be pondered in order to evaluate the risk of developing Long-COVID [1], [2]. However, we respectfully believe that these considerations are not pertinent to our study [3]. Indeed, we designed the LINCOLN (L-Arginine and Vitamin C improves Long-COVID) survey to determine whether a supplementation combining L-Arginine (to improve endothelial function) and Vitamin C (to reduce oxidation) could have favorable effects in patients with Long-COVID [3]. Thus, in our study we did not assess the risk of developing Long-COVID; in fact, as clearly specified in our article, all the enrolled patients had Long-COVID when the survey was administered. Nevertheless, potential differences in health conditions between the group that had received L-Arginine + Vitamin C and the group that had received the alternative treatment were ruled out by their family physicians. When comparing the two groups, we did not observe any significant difference in terms of age, sex, hospitalization due to COVID-19, and time from SARS-Cov-2 negativization. Moreover, bearing in mind the limitations that all surveys have, we had concluded our article stating that further dedicated interventional studies were warranted to endorse our findings.
Of note, we have previously conducted a randomized, double-blind, placebo-controlled, parallel-group, clinical trial testing the effects of L-Arginine oral supplementation in patients hospitalized for COVID-19, demonstrating that this treatment significantly decreases the length of hospitalization and reduces the respiratory support [4]. Additionally, we have identified endothelial exosomes enriched in miR-24 as a reliable biomarker to predict cerebrovascular complications of COVID-19 [5], corroborating the fundamental role of endothelial dysfunction in the pathobiology of COVID-19 and its clinical sequelae [6].
Funding
None.
Declarations of interest
None.
Data Availability
Data will be made available on request.
References
- 1.Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259–264. doi: 10.1038/s41586-021-03553-9. [DOI] [PubMed] [Google Scholar]
- 2.Subramanian A., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28:1706–1714. doi: 10.1038/s41591-022-01909-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Izzo R., et al. Combining L-Arginine with vitamin C improves long-COVID symptoms: the LINCOLN Survey. Pharm. Res. 2022;183 doi: 10.1016/j.phrs.2022.106360. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Fiorentino G., et al. Effects of adding L-arginine orally to standard therapy in patients with COVID-19: a randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis. eClinicalMedicine. 2021;40 doi: 10.1016/j.eclinm.2021.101125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Gambardella J., et al. Role of endothelial miR-24 in COVID-19 cerebrovascular events. Crit. Care. 2021;25:306. doi: 10.1186/s13054-021-03731-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Sardu C., et al. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J. Clin. Med. 2020;9 doi: 10.3390/jcm9051417. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data will be made available on request.